LATEST ARTICLES

mRNA startup Strand Therapeutics lands $52M to “program” new cancer therapies

  Messenger RNA brought the world its first Covid-19 vaccines, demonstrating along the way how this technology works. Strand Therapeutics is developing what could become the next generation of mRNA products: genetic circuits programmed with various features and functions, similar to the way writing computer code tells software how to execute multiple tasks. Already...

Priority Health to leverage data, partnerships for new social determinants initiative

Priority Health has launched a new data-driven social determinants of health initiative in collaboration with Socially Determined, ConsejoSano and Aunt Bertha. The Grand Rapids, Michigan-based health insurer plans to employ a “full lifecycle approach” to addressing social determinants of health, said Praveen Thadani, president of Priority Health, in an email. This means the insurer...

Scripps Health hit by 4 class-action lawsuits on heels of ransomware attack

Following a ransomware attack that disrupted its IT systems for nearly a month, Scripps Health is now facing four class-action lawsuits from patients for allegedly failing to protect their personal health information. In early May, the San Diego-based health system experienced a cybersecurity incident, which it later confirmed was a ransomware attack. In response,...

Mobile EHR startup DrChrono raises $12M, plans to build out telehealth features

  After launching a telehealth feature for its users earlier this year, health records startup DrChrono plans to build it out with $12 million in funding. The company recently raised a growth capital round led by ORIX Growth Capital, which led a debt financing for DrChrono last year.  After a challenging year for DrChrono’s...

Third Rock-backed Abata gets $95M to take cell therapy to MS, other autoimmune diseases

  Imagine an autoimmune disease treatment that activates only at the site of disease, shuts down inflammation from multiple sources, promotes tissue repair, and lasts for years. The source of this therapy, a type of immune cell, is already inside each and every one of us. Biotech startup Abata Therapeutics has raised $95 million...